Spruce Biosciences, Inc.

Spruce Biosciences is securing rights to a shelved BioMarin rare disease candidate in a bid to revive its pipeline – but it will need additional funding to get that program to market. On 15 April, the

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,

While it was technically successful, BridgeBio Pharma, Inc. ’s Phase I/II study of its gene therapy BBP-631 in congenital adrenal hyperplasia (CAH) did not quite deliver a strong enough result to jus

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur